• MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Psychiatric Times. All rights reserved.

5 Reports on Depression

August 10, 2018
James Murrough, MD, PhD

This special collection provides new insights on major aspects of depression: psychopharmacology, therapeutic interventions, major depressive episodes, biomarkers, and pseudobulbar affect.

Addressing Depression: The World’s Largest Health Problem. Despite the scope and magnitude of rising rates of depression and suicide, the field of psychiatry may be witnessing a turning point. Scroll through the slides for links to this 5-part collection.

The Psychopharmacology of Depression: Strategies, Formulations, and Future Implications. Recent findings suggest that the magnitude of efficacy for most antidepressants compared with placebo may be more modest than previously thought.

Psychotherapeutic Interventions for Depression: Which Work Best? In considering how best to disseminate the many psychotherapeutic techniques to practicing clinicians, the author reviews findings and changes to guidelines on depression treatments.

Major Depressive Episode: Is It Bipolar I or Unipolar Depression? Since the choice of treatments for a primary bipolar I disorder major depressive episode versus a unipolar major depressive episode are significantly different, this information will help guide clinicians in how to proceed.

 

Multimodal Markers and Biomarkers of Treatment. The use of biomarkers to assist with optimizing treatment decisions for depression has been receiving increasing attention. Here is an overview of the challenges and barriers that must be overcome before therapeutic markers can effectively be utilized in practice.

Pseudobulbar Affect Versus Depression: Issues in Diagnosis and Treatment. The most challenging aspect of pseudobulbar affect is differentiating it from depression. Episodes of uncontrollable, sudden, and even inappropriate emotions may point to neurologic or psychiatric conditions.

PreviousNext